Syros cans solid tumor drug after seeing early clinical data

Syros Pharmaceuticals' leadership team (Syros Pharmaceuticals)

Syros Pharmaceuticals has stopped development of its intravenous CDK7 inhibitor SY-1365 after early clinical data came up short. The lackluster results led Syros to switch its attention to an oral CDK7 inhibitor, SY-5609, that is due to enter the clinic early next year.

In August, Syros sketched out a series of upcoming milestones in the development of SY-1365 and talked up opportunities for accelerated development of the asset. Syros expected to pass the first milestone in the fourth quarter with the release of initial safety and efficacy data on the candidate in heavily pretreated ovarian cancer patients. 

Syros is yet to share data on the ovarian cancer patients, one of two populations targeted in the initial expansion of a phase 1 trial, but did provide a qualitative assessment of why it canned the drug. 

WEBINAR

Accelerate Clinical Operations Across Sponsors, CROs and Partners With a Best-of-Breed Partner Like Box

Tuesday, March 24 | 11am ET / 8am PT

Learn how Box is a critical force multiplier in the Best-of-Breed application stack with partners like Nintex, DocuSign and Slack in supporting clinical operations for both regulated and non-regulated content.

“Initial clinical activity and tolerability data from the expansion of the phase 1 trial of SY-1365 did not support an optimal profile for patients, particularly in light of an increasing focus on oral targeted agents in cancer,” Syros wrote in a statement.

SY-5609 is an oral molecule that Syros claims is a more selective and potent inhibitor of CDK7. In preclinical models, those advantages have translated into greater anti-tumor activity, according to Syros. 

However, while SY-5609 may be a better drug, the decision to scrap SY-1365 still pushes back Syros’ plans. SY-1365 was part of a two-pronged R&D push that Syros CEO Nancy Simonian saw as providing “fast-to-market strategies in three distinct AML and ovarian cancer patient populations” when she spoke to investors in August.

SY-5609 is further back in development. Syros plans to start a clinical trial of the asset in certain types of solid tumors in the first quarter of next year. The clinical timeline puts Syros well behind Carrick Therapeutics, which started a phase 1 trial of its oral CDK7 inhibitor CT7001 in 2017.

Shares in Syros fell 18% in premarket trading. 

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.